Building on pioneering work performed during the first wave of heart-lung transplantation, Brigham and Women’s Hospital has resumed its heart-lung program and is once again performing the rare procedure.
On November 10, 2018, the American Heart Association (AHA) held its annual Scientific Sessions meeting, featuring the latest advances from major cardiovascular trials with the potential to transform clinical practice. Investigators from the Brigham led some of the most highly anticipated trials and presented their results at the conference.
On October 19th, 2018, the HeartMate 3 Left Ventricular Assist System (LVAD) was approved by the FDA as a destination therapy for patients with advanced heart failure who are not eligible for a heart transplant.
The hybrid operating room at the Brigham and Women’s Hospital Heart & Vascular Center now features the state-of-art ARTIS Pheno angiography system. As of March 2018, patients who require hybrid cardiovascular interventions combining intravascular and open surgical procedures are reaping the rewards of this cutting-edge technology.
The history of surgery for valvular heart disease at Brigham and Women’s Hospital (BWH) dates to May 1923 when Elliott Carr Cutler, MD, performed the first ever valve operation in the world. Since then, BWH has been at the forefront of the clinical practice and innovation in the management of valve disease. Read More
A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American Heart Association Scientific Sessions, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, presented a pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. The results of this analysis, published simultaneously in The Lancet, could have a major impact not only on patient selection and cost-effectiveness of canakinumab, but also on the future development of anti-inflammatory agents for cardiovascular disease. Read More
Programs at Brigham and Women’s Hospital can assist you in caring for your patients with complex disorders, including evaluation and treatment for a range of abnormal heart rhythms.
Cardiac electrophysiologist and arrhythmia specialist Paul C. Zei, MD, PhD, joined the Heart Rhythm Disorders Program at Brigham and Women’s Hospital (BWH) as director of the Comprehensive Atrial Fibrillation Program (CAFP) with the goal of establishing it as one of the leading programs in the world for managing patients with atrial fibrillation (AF). Read More
Researchers have been able to generate induced pluripotent stem cells from patients with Hutchinson-Gilford progeria syndrome (HGPS) to better understand the mechanisms of aging and look for new treatments. Read More